Evaluation of neutron beam characteristics for D-BNCT01 facility

Chen, Junyang; Tong, Jianfei; Hu, Zhaosheng; Han, Xue-Fen; Tang, Bin; Yu, Qian; Zhang, Ruiqiang; Zhao, Changjun; Xu, Jun; Fu, Shinian; Zhou, Bin; Liang, Tianjiao

doi:10.1007/s41365-022-00996-1

Cited by 10 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BNCT device developed by the Institute of High Energy Physics (IHEP) of the Chinese Academy of Science uses a radio-frequency quadrupole (RFQ) linac accelerator. The first BNCT experimental device, D-BNCT01, has been built and installed with a proton energy of 3.5 MeV and an average flow intensity of 4.5 mA [ 24 , 25 ]. A fixed lithium target is used to generate neutrons.…”

Section: Recent Development and The Challengesmentioning

confidence: 99%

See 1 more Smart Citation

A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China

Zhang

Chong

Liu

et al. 2023

Cancers

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a promising cancer treatment modality that combines targeted boron agents and neutron irradiation to selectively destroy tumor cells. In mainland China, the clinical implementation of BNCT has made certain progress, primarily driven by the development of compact neutron source devices. The availability, ease of operation, and cost-effectiveness offered by these compact neutron sources make BNCT more accessible to cancer treatment centers. Two compact neutron sources, one being miniature reactor-based (IHNI-1) and the other one being accelerator-based (NeuPex), have entered the clinical research phase and are planned for medical device registration. Moreover, several accelerator-based neutron source devices employing different technical routes are currently under construction, further expanding the options for BNCT implementation. In addition, the development of compact neutron sources serves as an experimental platform for advancing the development of new boron agents. Several research teams are actively involved in the development of boron agents. Various types of third-generation boron agents have been tested and studied in vitro and in vivo. Compared to other radiotherapy therapies, BNCT in mainland China still faces specific challenges due to its limited clinical trial data and its technical support in a wide range of professional fields. To facilitate the widespread adoption of BNCT, it is crucial to establish relevant technical standards for neutron devices, boron agents, and treatment protocols.

show abstract

Section: Recent Development and The Challengesmentioning

confidence: 99%

“…D-BNCT01 is carried out for experimental research on BNCT-related technologies. At the same time, D-BNCT02 is designed for clinical usage [ 25 ]. D-BNCT02 is currently being installed and commissioned at the Dongguan People’s Hospital in Guangdong province.…”

Section: Recent Development and The Challengesmentioning

confidence: 99%